BioSpace News Archive

Business

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

IMUNON today reported financial results for the three months ended March 31, 2024.

May 13, 2024
·
15 min read
Biotech Beach

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Arcutis Biotherapeutics, Inc. announced that the Journal of Clinical and Aesthetic Dermatology published the outcomes of a comprehensive evaluation by an expert dermatologist panel assessing the formulation ingredients of ZORYVE topical foam, 0.3%.

May 13, 2024
·
6 min read
Business

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2024 financial results and provided a business update.

May 13, 2024
·
9 min read
Genetown

Collegium Announces $35 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. announced that it has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock.

May 13, 2024
·
4 min read
Business

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.

May 13, 2024
·
8 min read
Business

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

May 13, 2024
·
13 min read
Genetown

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

X4 Pharmaceuticals today announced that management will be participating in the upcoming H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City.

May 13, 2024
·
1 min read
Genetown

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Merus N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

May 13, 2024
·
8 min read
Policy

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and ComplianceScience 37’s Virtual Site Model for Clinical Research Impresses in First-of-its-Kind FDA Inspection

Science 37 Holdings, Inc. announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.

May 13, 2024
·
2 min read
Pharm Country

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

IN8bio presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy 2024 Annual Meeting.

May 13, 2024
·
5 min read